In a lengthy judgment, Justice Nicholas of the Federal Court of Australia has dismissed Sanofi’s appeal to overturn the decision of the Delegate of the Commissioner of Patents dismissing Sanofi’s opposition to the grant of five Amgen patent applications – AU2013203677, AU2013203748, AU2013203685, AU2013203689 and AU2013203751 (the Applications)
We have previously reported, twice, on the New Zealand government’s policy to allow the advertisement at medical conferences and trade shows of medicines not approved by the New Zealand medicines regulator, Medsafe.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 31 October 2025 are set out below…
When is a trade mark application filed in bad faith? Pearce IP’s Kimberley Evans discusses the recent trade mark decision of Rallen Australia Pty Limited v Tamboran Resources...
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 24 October 2025 are set out below…
This case was a successful application by Miele, the world-renowned cooking appliance manufacturer, to revoke relevant claims of AU2012247900 entitled “Hob with central removal of cooking vapours by suction-extraction in the downward direction” (the Patent), owned by the respondent, Bruckbauer.
Naomi Pearce, Pearce IP’s founder and CEO has been recognised as one of 70 Elite Women for 2025 by Australasian Lawyer, standing as a powerful symbol of what leadership can foster when excellence is balanced with the ability to allow others to thrive.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 17 October 2025 are set out below…
UPDATE: New Zealand intends to allow advertising of unapproved drugs at medical professional conferences…later. Earlier this year we reported on the New Zealand government’s announcement of a policy…
Pearce IP’s CEO, Naomi Pearce, discusses trends in preliminary injunctions in Australian life sciences patent cases with Head of Litigation (Australia), Helen Macpherson, following the recent Federal Court refusal of Regeneron’s and Bayer’s patent PI application against Sandoz relating to their AUD$500M/year blockbuster aflibercept (Eylea®).
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 10 October 2025 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 3 October 20252025 are set out below…
The Federal Court of Australia has handed down judgment in proceedings between Perfect Day, Inc. and the Commissioner of Patents, in an appeal from an opposition decision concerning a patent application for dairy substitute food compositions. Justice Rofe dismissed Perfect Day’s appeal and refused to allow the application to proceed to grant, finding that the claims failed to meet the heightened support and sufficiency requirements introduced under the ‘Raising the Bar’ amendments.
Justice Moshinsky of the Federal Court has delivered judgment in patent proceedings between The NOCO Company (NOCO) and Brown & Watson International Pty Ltd (B&W) relating to portable vehicle battery jump starters.
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 26 September 2025 are set out below…
It’s not often that the Australian Registrar of Trade Marks looks at disclaimers (which were a thing before the Trade Marks Act 1995 (Cth) came into force), but Hunchy Hills Distillery Pty Ltd [2025] ATMO 180 delivered by Hearing Officer Nicole Worth on 5 September 2025 is one such case.
Regeneron and Bayer have moved swiftly to appeal Justice Rofe’s decision denying Regeneron and Bayer’s application for PI on MOT patent AU2012205599…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 19 September 2025 are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the fortnight ending 12 September are set out below…
Pearce IP’s CEO, Naomi Pearce, discusses changes in New Zealand High Court procedure with our Head of Litigation (NZ), Paul Johns. As those changes are based on similar reforms made earlier in Australia, light is shed on their potential effects by the Head of Litigation (Australia), Helen Macpherson.
No interlocutory injunction (‘preliminary injunction’ or ‘PI’) has been granted in any pharmaceutical patent dispute since 2018. The Federal Court’s refusal last week of Regeneron and Bayer’s PI
Pearce IP is Australasian Lawyer and NZ Lawyer’s 5-Star Employer of Choice & “Standout Winner” for Inclusion and Culture (<100 employees)
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 29 August are set out below…
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the fortnight ending 22 August are set out below…
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
